A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Phase 1/2 Recruiting 123 enrolled Daiichi Sankyo Merck Sharp & Dohme LLC · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

Timeline

Start: 2024-07-22
Primary completion: 2026-09-30
Completion: 2026-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	—	Intravenous
Subject	Ifinatamab Deruxtecan	Other / unclassified	8 mg/kg	Intravenous
Subject	Ifinatamab Deruxtecan	Other / unclassified	12 mg/kg	Intravenous
Background	Atezolizumab	Monoclonal antibody	1200 mg	Intravenous

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Summary

Timeline

Drugs

Indications